Quick filters:
Open Data
Open Code
Pre-registered
Funding Declared
COI Declared
Open Access
Clear Filters
Ex-vivo rectal tissue infection with HIV-1 to assess time to protection following oral preexposure prophylaxis with ten…
Chawki S; Goldwirt L; Mouhebb ME; Gabassi A; Taouk M; Bichard I; Loze B; Amara A; Brand R; Siegel A; McGowan I; Costagliola D; Assoumou L; Molina JM; Delaugerre C; ANRS PREVENIR Study group.
AIDS
(Unknown)
Published: 2023
Cerebrospinal fluid pleocytosis is associated with HIV-1 neuroinvasion during acute infection.
Chan P; Moreland S; Sacdalan C; Kroon E; Colby D; Sriplienchan S; Pinyakorn S; Phanuphak N; Jagodzinski L; Valcour V; Vasan S; Paul R; Trautmann L; Spudich S; RV254/SEARCH 010 Study Team.
AIDS
(Unknown)
Published: 2023
Virological and immunological correlates of HIV posttreatment control after temporal antiretroviral therapy during acut…
van Paassen PM; van Pul L; van der Straten K; Buchholtz NVJE; Grobben M; van Nuenen AC; van Dort KA; Boeser-Nunnink BD; van den Essenburg MD; Burger JA; van Luin M; Jurriaans S; Sanders RW; Swelsen WT; Symons J; Klouwens MJ; Nijhuis M; van Gils MJ; Prins JM; de Bree GJ; Kootstra NA.
AIDS
(Unknown)
Published: 2023
Immunogenicity and reactogenicity of yellow fever vaccine in people with HIV.
Motta E; Camacho LAB; Cunha M; de Filippis AMB; Lima SMB; Costa M; Pedro L; Cardoso SW; Cortes FH; Giacoia-Gripp CBW; Morata M; Nazer S; Moreira RI; de Oliveira Souza MC; Mendes YS; Souza Azevedo A; Dos Santos Alvez N; Grinsztejn B; Coelho LE.
AIDS
(Unknown)
Published: 2023
Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada.
Costiniuk CT; Singer J; Lee T; Galipeau Y; McCluskie PS; Arnold C; Langlois MA; Needham J; Jenabian MA; Burchell AN; Samji H; Chambers C; Walmsley S; Ostrowski M; Kovacs C; Tan DHS; Harris M; Hull M; Brumme ZL; Lapointe HR; Brockman MA; Margolese S; Mandarino E; Samarani S; Vulesevic B; Lebouché B; Angel JB; Routy JP; Cooper CL; Anis AH; COVAXHIV Study Group.
AIDS
(Unknown)
Published: 2023
A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent…
Wilck M; Barnabas S; Chokephaibulkit K; Violari A; Kosalaraksa P; Yesypenko S; Chukhalova I; Dagan R; Richmond P; Mikviman E; Morgan L; Feemster K; Lupinacci R; Chiarappa J; Madhi SA; Bickham K; Musey L; V114-030 Study Group.
AIDS
(Unknown)
Published: 2023